New Perioperative Strategy in Gastric Cancer.
0/5 보강
APA
Shitara K (2025). New Perioperative Strategy in Gastric Cancer.. The New England journal of medicine, 393(3), 302-303. https://doi.org/10.1056/NEJMe2507207
MLA
Shitara K. "New Perioperative Strategy in Gastric Cancer.." The New England journal of medicine, vol. 393, no. 3, 2025, pp. 302-303.
PMID
40673590 ↗
같은 제1저자의 인용 많은 논문 (5)
- Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015.
- Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.
- First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
- Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies.
- Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.